Roche Holding AG (RHHBY) on Tuesday said its point-of-care test for diagnosing whooping cough, or pertussis, as well as other Bordetella infections, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver, alongside CE IVDR certification.
The PCR-based assay, designed for use on Roche's cobas liat system, can detect and differentiate between three types of Bordetella infections that often present with similar cough symptoms. The test delivers results in about 15 minutes.
Pertussis affects people of all ages but is particularly severe in children, contributing to an estimated 24.1 million cases and 170,000 deaths each year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.